How to Help Your Patients Save Money on Imipenem/Cilastatin: A Provider's Guide to Savings Programs

Imipenem/Cilastatin (Primaxin) is a hospital-based IV antibiotic with a cost structure that is fundamentally different from most outpatient drugs. As a provider, understanding how it's billed, covered, and what assistance programs exist can help you protect your patients from unexpected financial burden — particularly during a shortage when supply constraints may force alternatives that carry different cost implications. This guide covers the full landscape of cost management for Imipenem/Cilastatin.

Understanding the Cost Structure of an IV Antibiotic

Unlike a pill that's dispensed at a pharmacy and billed through the pharmacy benefit, Imipenem/Cilastatin is almost always administered in an institutional or clinical setting. This means:

• Inpatient administration: Bundled into the DRG or hospital day rate. Patients rarely see a separate line item for the antibiotic. Cost to the patient is determined by their hospital benefit (deductible, coinsurance, out-of-pocket max).

• Hospital outpatient infusion center: Billed as an outpatient facility claim. Medicare Part B covers 80% of approved charges after the Part B deductible; Medigap covers the remaining 20%. Commercial plans vary significantly.

• Home infusion / OPAT: Billed by the specialty infusion pharmacy. Medicare Part A covers home infusion only for certain conditions (hospice, skilled nursing); Part B covers very limited home infusion. Most OPAT patients rely on commercial insurance or Medicaid. Prior authorization is typically required.

• Outpatient pharmacy (rare): If dispensed as a fill-and-carry prescription, billed through pharmacy benefit. Cash price approximately $46–$303 for a course of vials depending on strength and quantity. Generic SingleCare price approximately $129.78 for 12 × 500 mg vials.

340B Drug Pricing: A Key Resource for Safety-Net Patients

If your institution participates in the 340B Drug Pricing Program, this is the single most powerful cost-reduction tool available for eligible patients. Under 340B, covered entities can purchase outpatient drugs (including Imipenem/Cilastatin) at deeply discounted prices — sometimes 20–50% below wholesale. Eligible patients typically include those who are uninsured, underinsured, or enrolled in Medicaid and receive care through the 340B covered entity.

Action step: Involve your hospital's 340B program coordinator early in the treatment planning process for uninsured or financially struggling patients. They can determine eligibility and route the prescription through the 340B pharmacy.

Medicaid Coverage

Medicaid covers IV antibiotics administered in hospital and infusion settings with minimal to no patient cost share in most states. For OPAT under Medicaid, coverage of home infusion pharmacy services varies significantly by state — some states have robust home infusion benefits, others require patients to be in a skilled nursing facility. Check your state's Medicaid coverage policies for home infusion before committing a Medicaid patient to an OPAT program.

Prior Authorization for OPAT: What Providers Need to Know

Prior authorization (PA) is often required by commercial insurers and some Medicare Advantage plans for home infusion therapy (OPAT). This is a common source of costly delays at discharge. Key PA considerations:

• Start the PA process 48–72 hours before anticipated discharge: PA approvals can take 1–2 business days. Starting early prevents discharge delays and medication gaps.

• Include culture and sensitivity data: Insurers want evidence that the specific antibiotic chosen is medically necessary — that the organism is susceptible and that narrower-spectrum agents are not appropriate. Attach culture reports to PA requests.

• Document shortage-related decisions: If you had to switch from another antibiotic to Imipenem/Cilastatin due to supply constraints, document this clearly. Insurers may question why a carbapenem was chosen over a narrower agent.

• Have the infusion pharmacy assist with PA: Specialty infusion pharmacies (Coram, BrightSpring, Aveanna, PharMerica) routinely handle PA requests for home infusion antibiotics. Involve them early.

Manufacturer Assistance Programs

Generic Imipenem/Cilastatin (Fresenius Kabi, Pfizer/Hospira) does not have manufacturer patient assistance programs or copay cards. These are generic injectable products and are not supported by commercial savings programs.

Brand Primaxin IV (Merck): Qualifying patients may contact Merck's patient assistance program (Merck Helps) at 1-800-727-5400. Eligibility requirements apply based on income and insurance status.

Hospital Financial Counseling and Charity Care

For uninsured or underinsured patients who receive Imipenem/Cilastatin during a hospitalization, refer them to your hospital's financial counseling team before discharge. Most nonprofit hospitals are required to have charity care or financial assistance programs under the Affordable Care Act's community benefit requirements. Patients who qualify may have their hospital charges (including IV antibiotics) significantly reduced or eliminated.

Cost Implications of Switching to an Alternative During Shortage

If Imipenem/Cilastatin is unavailable and you switch to an alternative, be aware of cost differences for your patient:

• Meropenem: Generic meropenem is similarly priced to generic imipenem/cilastatin. Good cost-equivalent alternative.

• Ertapenem: Generic ertapenem is widely available and competitively priced. Once-daily dosing may also reduce infusion pharmacy administration costs for OPAT programs.

• Ceftazidime-Avibactam (Avycaz): Significantly more expensive (often $5,000–$15,000+ per course). Prior authorization is uniformly required. Reserved for documented resistant organisms — do not use as a shortage substitute without a clear clinical indication.

How medfinder Supports Access for Your Patients

Access to the right antibiotic is prerequisite to managing its cost. During the 2026 shortage, medfinder for providers helps your discharge planning team and patients' caregivers locate pharmacies and infusion centers with current Imipenem/Cilastatin stock — avoiding treatment gaps and costly alternative antibiotic escalations. medfinder calls pharmacies directly and reports back availability so your team doesn't have to spend hours on hold.

For your patients' reference, see our patient-facing guide on how to save money on Imipenem/Cilastatin including coupon options, insurance billing, and assistance programs.